24. August 2023 – Future Health Pharma GmbH submitted the authorisation application on behalf of Novavax. The application concerns the updated Nuvaxovid monovalent COVID-19 vaccine from Novavax. The protein-based vaccine contains a non-infectious component from the surface of SaRS-CoV-2 Omicron subvariant XBB.1.5., which triggers a protective immune response when the body’s immune cells come into contact with it. Swissmedic is examining the application.

For more information, see here.